

Original research article**Resurgence of cardiovascular diseases in patients recovered from COVID-19: An Indian perspective****¹Dr. Manbahadur Rajpoot, ²Dr. Surendra Singh Yadav, ³Dr. Parul Nema, ⁴Dr. Vishnu Kumar, ⁵Dr. Rajesh Kumar Ahirwar**¹Assistant Professor, Department of Community Medicine, SRVS Medical College, Shivpuri, Madhya Pradesh, India²Assistant Professor, Department of Cardiothoracic and Vascular Surgery, AIIMS, Bhopal, Madhya Pradesh, India³Assistant Professor, Department of Pathology, SRVS Medical College, Shivpuri, Madhya Pradesh, India⁴Senior Resident (Demonstrator), Department of Community Medicine, SRVS Medical College, Shivpuri, Madhya Pradesh, M.P. India⁵Professor & Head, Department of Community Medicine, SRVS Medical College, Shivpuri, Madhya Pradesh, India**Corresponding Author:**Dr. Parul Nema (drparulnema@gmail.com)**Abstract****Background:** Most common cardio vascular disease events after COVID-19 were hypertension, pulmonary embolism, acute coronary syndrome, myocarditis, stress-Cardiomyopathy, arrhythmias, carcinogenic shock, and cardiac arrest.**Aim:** The aim of this study was to analyze the onset of post-COVID-19 cardiovascular events in patients hospitalized in a tertiary care center**Methods:** This retrospective observational study was carried out in the department of medicine in a tertiary care hospital, central India. Asses all the participants for post covid cardio vascular events, detailed history, clinical examination and all necessary investigation was done**Results:** in our study Post COVID 19 cardio vascular events was occur in 17.5%. Majority of the patient was male (68.6%), most common age group were 51-60 years. Higher incidence of cardio vascular disease was reported in obese person. Common cardio vascular diseases found after COVID 19 infection were, hypertension (35.7%), pulmonary embolism (22.9%), Myocarditis (20%), myocardial infection (11.4%) and Arrhythmias were in 10% cases.**Conclusion:** Overall observations indicate an increased incidence of hypertension and CVDs post recovery from COVID-19. A dual therapy of ARBs was the preferred choice for management of hypertension. Regular follow-up and close monitoring of symptoms to prevent further CV complications in COVID-19 recovered patients is recommended.**Keywords:** Cardio-vascular, disease events, COVID 19, hypertension, obesity**Introduction**

Corona virus disease 2019 (COVID-19) has presented with a heterogeneous clinical course, ranging from asymptomatic carrier state to a lethal outcome with multi-organ failure and with a wide variety of case fatality rates ranging from 0.7 to 67% [1-2]. Although the respiratory tract is the most commonly involved organ system in this disease, other organs and particularly the heart are also affected with a negative impact on outcome [3]. Post-acute sequelae of SARS-CoV-2-the virus that causes corona virus disease 2019 (COVID-19)-can involve the pulmonary and several extrapulmonary organs, including the cardiovascular system [4]. The patients with covid-19 with cardiovascular comorbidities have higher mortality, and the severity of COVID-19 disease correlates with cardiovascular manifestations [5-6]. Hypertension (HTN) is the major risk factor to cardiovascular (CV) morbidity and mortality in India and is responsible for 28% of total deaths. Studies report that HTN and cardiovascular diseases (CVD) are the most frequent co-morbidities in patients with COVID-19 infection [7-8]. COVID-19 significantly impacts CV system by causing complications such as acute coronary syndrome and myocardial infarction, blood pressure fluctuations or worsening pre-existing CVDs [9]. COVID-19 with secondary to acute lung injury leads to increased cardiac workload, potentially challenging in patients with pre-existing heart failure, acute cardiac injury, myocardial injury, arrhythmias. Prominent increase in cardiac troponin levels is reported that is associated with other inflammatory markers, such as C-reactive protein, ferritin, and interleukin-6, suggesting inflammatory damage leading to myocarditis [10]. The aim of this study was to analyze the incidence of cardiovascular events in patients hospitalized for

SARS-CoV-2 infection.

Material & Methods

This was a retrospective, observational cohort study carried out in the department of medicine, a tertiary care center, central India. The study population was adults (≥18 years) with COVID-19 confirmed by polymerase chain reaction (PCR). All subjects who survived had a 30-day follow up after hospital discharge. Data on baseline signs, symptoms, comorbidities, treatments, outcomes, blood count, and biochemical and cardiac markers were collected. All data, including electrocardiograms (ECGs), were electronically recorded. The serum level of hypersensitive troponin I (cTnI) exceeding >40 pg/ml was considered cardiac injury [11]. Blood pressures were obtained three fixed times in the morning using standard measurement. History of hypertension was defined as brachial blood pressure > 140/90 mmHg. Myocarditis was suspected in post covid patients by echocardiography and ECG findings. Cardiovascular events were diagnosed according to standard guidelines.

Statistical analysis: Data was entered into Microsoft Excel and analyzed using SPSS software version 20. Pearson’s Chi Square test was applied. P value< 0.05 was considered significant.

Results

During the observation period, 400 patients were enrolled, out of them 70 (17.5%) were developed cardiovascular events after COVID 19 infection.




Fig 1: Development of cardio vascular events in patients recovered from COVID 19

Majority of the study participant (68.6%) were male. 52.8% residing at urban areas. Family history of cardio vascular disease was present in 24.3% cases. Most of the participant had obese (70%) [Table: 1].

Table 1: General characteristics of the patients devolved cardiovascular disease events (n=70)

General characteristics		Number (N=70)	Percentage
Gender	Male	48	68.6%
	Female	22	31.4%
Place of residence	Urban	37	52.8%
	Rural	33	47.2%
Family history of cardio-vascular disease	Absent	53	75.7%
	Present	17	24.3%
BMI	Normal	21	30%
	Mild obesity	23	32.8%
	Moderate obesity	16	22.9%
	Severe obesity	10	14.3%

Common cardiovascular events developed after COVID 19 were hypertension (35.7%), pulmonary embolism (22.9%), Myocarditis (20%), Myocardial infarction. (11.4%) and Arrhythmias was (10%). [Table: 2].

Table 2: Development of cardiovascular disease events after COVID 19

Cardiovascular events	Number (70)	Percentage
Hypertension	25	35.7%
Pulmonary embolism	16	22.9%
Myocarditis	14	20%
Arrhythmias	7	10%
Myocardial infarction	8	11.4%

Table 3: Comparison between patients who developed cardiovascular events and patients who did not

Socio demographic variables		Patients with cardiovascular event (N=70)	Patients with no cardiovascular event (N=370)	P-value
Age (in years)	18-30	10 (14.2%)	52 (14.1%)	0.999
	31-40	13 (18.6%)	67 (18.1%)	
	41-50	16 (22.9%)	84 (22.7%)	
	51-60	24 (34.3%)	130 (35.1%)	
	>60 years	7 (10%)	37 (10%)	
Gender	Male	40 (57.1%)	215 (58.1%)	0.880
	Female	30 (42.9%)	155 (41.9%)	
Body Mass Index (Kg/M ²)	Normal (<25)	24 (34.3%)	128 (34.6%)	0.996
	Over weight (25-30)	17 (24.3%)	87 (23.5%)	
	Obese (31-40)	21 (30%)	115 (31.1%)	
	>40 (morbid obesity)	8 (11.4%)	40 (10.8%)	
Comorbidities	Diabetes	33 (47.1%)	161 (43.5%)	0.994
	Hypertension	39 (55.7%)	211 (57%)	
	Previous CVD	21 (30%)	92 (24.9%)	
	Chronic renal disease	16 (22.9%)	78 (21.1%)	
	Hematological disease	12 (17.1%)	57 (15.4%)	
	Neoplastic disease	8 (11.4%)	39 (10.5%)	

Discussion

A large number of patients with COVID-19 have pre-existing HTN and/or CVD or may develop new onset HTN and cardiac diseases during the course of infection. However, the understanding about their impact on the clinical outcomes in COVID-19 is still ambiguous.

Incidence of cardio vascular disease events was occurs in 17.6% of COVID-19 patients in our study, consistent finding also reported by C. Lazaridis et al [12]. And Momtazmanesh et al [13].

In present study the most common cardio vascular disease events after COVID-19 were, hypertension, pulmonary embolism, acute coronary syndrome, myocarditis, stress-Cardiomyopathy, arrhythmias, carcinogenic shock and cardiac arrest, our finding are similar to other studies: Kang Y, et al [14] and Sala S et al. [15].

In our study majority of the study participant (69.4%) was male, concordance with the Xie Y et al. [16] and Chen G, et al [17], reported male predominance in their study.

Current study was found obesity was the major risk factor of cardio vascular diseases after COVID 19, our finding are comparable with the many other studies, Wu X et al [18] and Tadic M et al [19].

COVID-19 infection is associated with an increase in the incidence and burden of long-term CVD, including arrhythmias, ischemic and non-ischemic heart disease, myopericarditis, ischemic stroke and venous thromboembolism [20].

Most of the study population was belong to urban area (53.2%), concordance finding reported by Valentina O et al [21].

In our study majority of the cardio vascular disease event patient s were 51-60 years age group, similar to the study conducted by Collard D, et al [22] and Wang W et al [23].

Diabetes and hypertension was the most common cardio vascular disease event occur in COVID 19 observed in current study, which was similar to the Krishnakumar B et al [24] and Cuomo C et al [25].

The Government of India, Ministry of health & family welfare declared a post COVID-19 management protocol with a holistic approach to all the physicians and patients for further follow-up care and well-being of all the patients recovering from COVID-19 [26].

Conclusion

Patients can develop CV conditions, new onset HTN and exacerbations of pre-existing comorbidities such as HTN, CVD, diabetes and dyslipidemia after recovering from COVID-19. Therefore, early recognition, prevention and strategic methods are vital factors that will help to prevent further complications post COVID-19 recovery. The timely management of HTN, diabetes, and CV complications and follow-up of HCP’s advice on treatment recommendations will definitely ensure the best possible outcomes in COVID-19 recovered patients.

Conflict of interest: None.

Source of funding: None.

References

- Lai CC, Liu YH, Wang CY, *et al.* Asymptomatic carrier state, acute respiratory disease and pneumonia due to severe acute respiratory syndrome corona virus 2 (SARS-CoV-2): Facts and myths. *J Microbiol Immunol Infect*; c2020.
- Arentz M, Yim E, Klaff L, *et al.* Characteristics and Outcomes of 21 Critically Ill Patients with COVID-19 in Washington State. *JAMA*; c2020.
- Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nature Reviews Cardiology*. 2020;17:259-260.
- Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature*. 2021;594:259-264.
- China CDC. The epidemiological characteristics of an outbreak of 2019 novel corona virus diseases (COVID-19)-China, 2020. *China CDC Weekly*. 2020;2:113-22.
- Guo T, Fan Y, Chen M, *et al.* Cardiovascular implications of fatal outcomes of patients with corona virus disease 2019 (COVID-19). *JAMA Cardiol*; c2020.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, *et al.* Clinical features of patients infected with 2019 novel corona virus in Wuhan, China. *Lancet*. 2020;395:497-506.
- Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, *et al.* Clinical characteristics of corona virus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. *J Infect*. 2020;80:656-65.
- Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of corona viruses on the cardiovascular system a review. *JAMA Cardiol*. 2020;5:831-40.
- Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of COVID-19: Mechanisms underlying disease severity and progression. *Physiology (Bethesda)*. 2020;35:288-301.
- Bonaca M, Scirica B, Sabatine M, Dalby A, Spinar J, Murphy SA, *et al.* Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. *J Am Coll Cardiol*. 2010;55:2118-24.
- Charalampos Lazaridis, Nikolaos I Vlachogiannis, Constantinos Bakogiannis, Ioakim Spyridopoulos, Kimon Stamatelopoulos, Ioannis Kanakakis, *et al.* Involvement of cardiovascular system as the critical point in corona virus disease 2019 (COVID-19) prognosis and recovery, *Hellenic Journal of Cardiology*. 2020;61:381-e395.
- Sara Momtazmanesh, Parnian Shobeiri, Sara Hanaei, Hani Mahmoud-Elsayed, Bharat Dalvi, Elaheh Malakan Rad. Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool, *The Egyptian Heart Journal*. 2020;72:41.
- Yu Kang, Tiffany Chen, David Mui, Victor Ferrari, Dinesh Jagasia, Marielle Scherrer-Crosbie, *et al.* Cardiovascular manifestations and treatment considerations in COVID-19 *Heart*. 2020;106:1132-1141.
- Sala S, Peretto G, Gramegna M, *et al.* Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. *Eur. Heart J*; c2020. Doi:10.1093/eurheartj/ehaa286.
- Yan Xie, Evan Xu, Benjamin Bowe, Ziyad Al-Aly. Long-term cardiovascular outcomes of COVID-19, *Nature Medicine*. 2022 March;28:583-590.
- Chen G, Li X, Gong Z, Xia H, Wang Y, Wang X, *et al.* Hypertension as a sequela in patients of SARS-CoV-2 infection. *PLoS ONE*. 2021;16(4):e025-0815. <https://doi.org/10.1371/journal.pone.0250815>.
- Wu X, Deng KQ, Li C, Yang Z, Hu H, Cai H, *et al.* Cardiac Involvement in Recovered Patients From COVID-19: A Preliminary 6-Month Follow-Up Study. *Front. Cardiovasc. Med*. 2021;8:654-405.
- Tadic M, Saeed S, Grassi G, Taddei S, Mancia G, Cuspidi C. Hypertension and COVID-19: Ongoing Controversies. *Front. Cardiovasc. Med*. 2021;8:639-222.
- Julie Coursen MD, Allison G Hays, MDFACC, Anum Minhas MD, Roger S, Blumenthal MD. FACC COVID-19 Increases Long-Term Risk of Ischemic and Non-Ischemic Cardiovascular Disease, *American College of Cardiology*; c2022 May.
- Valentina O Puntmann, Ludovica Carerj M, Imke Wieters, Masia Fahim, Christophe Arendt, Jędrzej Hoffmann, *et al.* Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Corona virus Disease 2019 (COVID-19), *JAMA Cardiol*. 2020;5(11):1265-1273.
- Collard D, Nurmohamed NS, Kaiser Y, *et al.* Cardiovascular risk factors and COVID-19 outcomes in hospitalized patients: a prospective cohort study. *BMJ Open*. 2021;11:e045-482. Doi:10.1136/bmjopen-2020-045482.

23. Weijie Wang, Chi-Yen Wang, Shio-Ing Wang, James Cheng-Chung We. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: A retrospective cohort study from the TriNetX US collaborative networks, articles, 2022, 53. www.thelancet.com.
24. Krishnakumar B, Christopher J, Prasobh PS, Godbole S, Mehrotra A, Singhal A, *etal*. Resurgence of hypertension and cardiovascular diseases in patients recovered from COVID-19: An Indian perspective. *J Family Med Prim Care*. 2022;11:2589-96.
25. Gianluca Cuomo, Cinzia Puzzolante, Vittorio Iadisernia, Antonella Santoro, Marianna Menozzi, *et al.*, Development of post-COVID-19 cardiovascular events: an analysis of clinical features and risk factors from a single hospital retrospective study, *Le Infezioni in Medicina*. 2021;4:538-549.
26. Post COVID management protocol. Available from: <https://www.mohfw.gov.in/pdf/PostCOVID13092020.pdf>. [Last accessed on 2021 Mar 22].